This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Vical Reports Second Quarter 2013 Financial Results, Projects Phase 3 Data Release In August And Establishes Quiet Period

SAN DIEGO, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2013. Revenues were $1.5 million for the second quarter of 2013 compared with $1.6 million for the second quarter of 2012, reflecting ongoing reimbursements from Astellas Pharma Inc. for expenses related to the development of ASP0113 (TransVax™), Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients. The net loss was $9.9 million, or $0.11 per share, for the second quarter of 2013, compared with $7.9 million, or $0.09 per share, for the second quarter of 2012.

Revenues were $3.0 million for the first half of 2013 compared with $13.0 million for the first half of 2012. The 2012 revenue includes the recognition of a $10 million milestone payment from Astellas for progress with ASP0113 which occurred in the first quarter of 2012. The net loss was $19.2 million, or $0.22 per share, for the first half of 2013, compared with $7.6 million, or $0.09 per share, for the first half of 2012.

Vical had cash and investments of approximately $70 million at June 30, 2013. The company's net cash uses in the first half of 2013 were slightly below the company's forecast range. The company expects to provide net cash use guidance for the second half of 2013 after analyzing the financial implications of results from its Phase 3 registration trial of Allovectin ®.

Program highlights include:

Allovectin ®

  • Top-line results from the company's Phase 3 registration trial of Allovectin ®, previously projected for release in the third quarter of 2013, are now expected to be released in August.
  • Following today's scheduled conference call, as described below, and extending until the release of top-line results, the company will enter a self-imposed quiet period during which time company management will not be interacting substantively with the investment community.

ASP0113 CMV Vaccine

  • Astellas initiated a 500-patient Phase 3 trial of ASP0113 for hematopoietic cell transplant (HCT) recipients in June and expects to initiate a Phase 2 trial of ASP0113 for solid organ transplant (SOT) recipients later this year. Details of the Phase 3 trial design will be discussed in today's scheduled conference call, as described below.

Herpes Simplex Vaccine

  • The company is planning to initiate a Phase 1/2 clinical trial of its Vaxfectin ®-formulated therapeutic vaccine against herpes simplex virus type 2 (HSV-2) in the second half of 2013.

Conference Call

Vical will conduct a conference call and webcast today, August 1, at noon Eastern Time, to discuss the company's financial results and program updates with invited participants. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2464 (preferred), or (888) 455-2263 (toll-free), and reference confirmation code 1123209. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 1123209. The call also will be available live and archived through the events page at www.vical.com . For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at ir@vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com .

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include net cash use guidance, as well as anticipated developments in independent and collaborative programs, including the initiation and completion of clinical trials. Risks and uncertainties include whether Vical or others will continue development of Allovectin ®, the HSV-2 vaccine, or any other independent or collaborative programs; whether Vical, Astellas or others will continue development of ASP0113; whether the company will release top-line results from its Phase 3 registration trial of Allovectin ® in patients with metastatic melanoma before the end of August; whether the company will provide net cash use guidance for the second half of 2013 after releasing top-line results from its Phase 3 registration trial of Allovectin ®, if at all; whether Astellas will initiate the planned Phase 2 trial of ASP0113 for SOT recipients later this year, if at all; whether Vical or others will initiate a Phase 1/2 clinical trial of the HSV-2 vaccine in the second half of 2013, if at all; whether Vical will achieve levels of revenues and control expenses to meet its financial projections; whether any product candidates will be shown to be safe and efficacious in clinical trials; the timing of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

 
VICAL INCORPORATED
Selected Condensed Financial Information (Unaudited)
         
Statements of Operations Three Months Ended June 30, Six Months Ended June 30,
(in thousands, except per share amounts) 2013 2012 2013 2012
Revenues:        
Contract and grant revenue  $ 1,170  $ 1,364  $ 2,306  $ 2,585
License and royalty revenue  286  201  724  10,440
Total revenues  1,456  1,565  3,030  13,025
Operating expenses:        
Research and development  3,930  3,791  7,580  10,219
Manufacturing and production  3,891  2,933  7,604  5,405
General and administrative  3,478  2,778  6,996  5,478
Total operating expenses  11,299  9,502  22,180  21,102
Loss from operations  (9,843)  (7,937)  (19,150)  (8,077)
Net investment and other income (expense)  (38)  69  (13)  453
Net loss  $ (9,881)  $ (7,868)  $ (19,163)  $ (7,624)
Basic and diluted net loss per share  $ (0.11)  $ (0.09)  $ (0.22)  $ (0.09)
Weighted average shares used in computing basic and diluted net loss per share  86,730  86,282  86,623  85,412
         
         
Balance Sheets     June 30, December 31,
(in thousands)     2013 2012
Assets:        
Cash, cash equivalents, and marketable securities, including restricted      $ 67,498  $ 83,857
Other current assets      2,083  2,152
Total current assets      69,581  86,009
Long-term investments      2,037  2,225
Property and equipment, net      4,735  5,284
Other assets      2,932  3,004
Total assets      $ 79,285  $ 96,522
         
Liabilities and stockholders' equity:        
Current liabilities      $ 6,059  $ 5,779
Long-term liabilities      1,483  1,657
Stockholders' equity      71,743  89,086
Total liabilities and stockholders' equity      $ 79,285  $ 96,522
CONTACT: Alan R. Engbring
         (858) 646-1127
         Website:  www.vical.com

Vical Logo

Stock quotes in this article: VICL 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,501.65 0.00 0.00%
S&P 500 1,878.61 +3.22 0.17%
NASDAQ 4,148.3380 +21.3710 0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs